Browse AK5

Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain -
Function

Nucleoside monophosphate (NMP) kinase that catalyzes the reversible transfer of the terminal phosphate group between nucleoside triphosphates and monophosphates. Active on AMP and dAMP with ATP as a donor. When GTP is used as phosphate donor, the enzyme phosphorylates AMP, CMP, and to a small extent dCMP. Also displays broad nucleoside diphosphate kinase activity.

> Gene Ontology
 
Biological Process GO:0006164 purine nucleotide biosynthetic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006172 ADP biosynthetic process
GO:0006173 dADP biosynthetic process
GO:0006220 pyrimidine nucleotide metabolic process
GO:0006221 pyrimidine nucleotide biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009124 nucleoside monophosphate biosynthetic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009127 purine nucleoside monophosphate biosynthetic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009133 nucleoside diphosphate biosynthetic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009136 purine nucleoside diphosphate biosynthetic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009142 nucleoside triphosphate biosynthetic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009151 purine deoxyribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009153 purine deoxyribonucleotide biosynthetic process
GO:0009156 ribonucleoside monophosphate biosynthetic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009168 purine ribonucleoside monophosphate biosynthetic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009180 purine ribonucleoside diphosphate biosynthetic process
GO:0009182 purine deoxyribonucleoside diphosphate metabolic process
GO:0009183 purine deoxyribonucleoside diphosphate biosynthetic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009186 deoxyribonucleoside diphosphate metabolic process
GO:0009188 ribonucleoside diphosphate biosynthetic process
GO:0009189 deoxyribonucleoside diphosphate biosynthetic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009218 pyrimidine ribonucleotide metabolic process
GO:0009220 pyrimidine ribonucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009262 deoxyribonucleotide metabolic process
GO:0009263 deoxyribonucleotide biosynthetic process
GO:0009265 2'-deoxyribonucleotide biosynthetic process
GO:0009394 2'-deoxyribonucleotide metabolic process
GO:0015949 nucleobase-containing small molecule interconversion
GO:0019692 deoxyribose phosphate metabolic process
GO:0042278 purine nucleoside metabolic process
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0046031 ADP metabolic process
GO:0046034 ATP metabolic process
GO:0046056 dADP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046385 deoxyribose phosphate biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046939 nucleotide phosphorylation
GO:0072522 purine-containing compound biosynthetic process
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004017 adenylate kinase activity
GO:0004550 nucleoside diphosphate kinase activity
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0019201 nucleotide kinase activity
GO:0019205 nucleobase-containing compound kinase activity
GO:0019206 nucleoside kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
hsa00730 Thiamine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-499943: Synthesis and interconversion of nucleotide di- and triphosphates
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AK5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AK5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AK5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0840.792
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1480.777
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0470.922
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1560.016
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3210.308
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9530.517
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0880.892
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3190.744
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0640.949
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0170.984
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0510.963
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1120.626
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AK5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AK5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AK5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AK5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AK5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AK5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AK5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAK5
Nameadenylate kinase 5
Aliases AK 5; ATP-AMP transphosphorylase 5; Adenylate kinase isoenzyme 5
Chromosomal Location1p31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AK5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.